Mary Talley Bowden, MD, founder of Americans for Health Freedom, an advocacy group that has lobbied against mRNA shots, ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

By pairing an mRNA-style vaccine with traditional cancer immunotherapy drugs known as immune checkpoint inhibitors, they were ...

A Turkish study finds Pfizer’s COVID-19 vaccine may cause temporary changes in corneal thickness and cell count, raising concerns for those with existing eye issues or transplants.

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...

A team of researchers in Turkey have discovered multiple signs of stress in the eye after patients took Pfizer's COVID-19 ...

Scientists have discovered that Pfizer's COVID-19 vaccine may increase the risk of eye damage, leading to vision loss.The new study specifically examined how ...

A new scientific study has found that Pfizer’s COVID-19 vaccine may cause temporary changes in the eyes’ corneal structure, ...

In this week’s edition of InnovationRx, we look at Moderna’s use of quantum computers, a new top drug regulator at the FDA, ...

Thursday, July 24, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems ...

The race to develop effective cancer vaccines has entered a new phase, with late-stage trials from companies like Moderna ...